Ann: Sensera completes A$2.5m private placement, page-188

See the quote below … from mid-2020, there was talk of a multiplex test back then. This may well be the reason for the excessive delay from NanoDX and the IBM technology makes it feasible ( from my basic understanding). Gee, I hope this is the case, what a game changer.

”In the case of the SARS-CoV-2 antigen test, the nanowire is functionalized with an antibody to detect the spike protein that is specific to COVID-19. Because of the capability to functionalize the nanowire with many different types of antibodies, NanoDx is also looking into developing a multiplex test that would detect and differentiate between SARS-CoV-2 and influenza, Joshi said.”